The value of innovation in decision-making in health care in Central Eastern Europe: The sixth international conference, 2 June 2017, Belgrade, Serbia

Tanja Novakovic, Antony P. Martin, Mark Parker, Alessandra Ferrario, Simo Vukovic, Krzysztof Łanda, Jaroslav Duba, Dávid Dankó, Nikolaos Kotsopoulos, Brian Godman, Jelena Ristic, Danka Stefanovic, Danka Tesic

Research output: Contribution to journalArticle

  • 1 Citations

Abstract

The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia organised a one day international conference on the value of innovation in decision-making in health care in Central and Eastern Europe. The focus of the conference was on reimbursement decisions for medicines using health technology assessment and the use of managed entry agreements (MEAs). The objectives of this conference were firstly to discuss the challenges and opportunities with the use of MEAs in Central and Eastern European countries; secondly the role of patient registries especially with outcome based schemes, and finally new approaches to improve accessibility to new medicines including better managing their entry.
LanguageEnglish
Pages519-521
Number of pages3
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume17
Issue number6
Early online date9 Oct 2017
DOIs
StatePublished - 31 Dec 2017

Fingerprint

Serbia
Eastern Europe
Decision Making
Delivery of Health Care
Pharmaceutical Economics
Biomedical Technology Assessment
Registries
Pharmaceutical Preparations

Keywords

  • managed entry agreements
  • health technology assessment
  • innovation
  • Central and Eastern Europe

Cite this

Novakovic, Tanja ; Martin, Antony P. ; Parker, Mark ; Ferrario, Alessandra ; Vukovic, Simo ; Łanda, Krzysztof ; Duba, Jaroslav ; Dankó, Dávid ; Kotsopoulos, Nikolaos ; Godman, Brian ; Ristic, Jelena ; Stefanovic, Danka ; Tesic, Danka. / The value of innovation in decision-making in health care in Central Eastern Europe : The sixth international conference, 2 June 2017, Belgrade, Serbia. In: Expert Review of Pharmacoeconomics and Outcomes Research. 2017 ; Vol. 17, No. 6. pp. 519-521
@article{7de4e4d9661c4f1383de590b4e2a2a1a,
title = "The value of innovation in decision-making in health care in Central Eastern Europe: The sixth international conference, 2 June 2017, Belgrade, Serbia",
abstract = "The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia organised a one day international conference on the value of innovation in decision-making in health care in Central and Eastern Europe. The focus of the conference was on reimbursement decisions for medicines using health technology assessment and the use of managed entry agreements (MEAs). The objectives of this conference were firstly to discuss the challenges and opportunities with the use of MEAs in Central and Eastern European countries; secondly the role of patient registries especially with outcome based schemes, and finally new approaches to improve accessibility to new medicines including better managing their entry.",
keywords = "managed entry agreements, health technology assessment, innovation , Central and Eastern Europe",
author = "Tanja Novakovic and Martin, {Antony P.} and Mark Parker and Alessandra Ferrario and Simo Vukovic and Krzysztof Łanda and Jaroslav Duba and D{\'a}vid Dank{\'o} and Nikolaos Kotsopoulos and Brian Godman and Jelena Ristic and Danka Stefanovic and Danka Tesic",
year = "2017",
month = "12",
day = "31",
doi = "10.1080/14737167.2017.1385394",
language = "English",
volume = "17",
pages = "519--521",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
number = "6",

}

Novakovic, T, Martin, AP, Parker, M, Ferrario, A, Vukovic, S, Łanda, K, Duba, J, Dankó, D, Kotsopoulos, N, Godman, B, Ristic, J, Stefanovic, D & Tesic, D 2017, 'The value of innovation in decision-making in health care in Central Eastern Europe: The sixth international conference, 2 June 2017, Belgrade, Serbia' Expert Review of Pharmacoeconomics and Outcomes Research, vol. 17, no. 6, pp. 519-521. DOI: 10.1080/14737167.2017.1385394

The value of innovation in decision-making in health care in Central Eastern Europe : The sixth international conference, 2 June 2017, Belgrade, Serbia. / Novakovic, Tanja; Martin, Antony P.; Parker, Mark; Ferrario, Alessandra; Vukovic, Simo; Łanda, Krzysztof; Duba, Jaroslav; Dankó, Dávid; Kotsopoulos, Nikolaos; Godman, Brian; Ristic, Jelena; Stefanovic, Danka; Tesic, Danka.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 17, No. 6, 31.12.2017, p. 519-521.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The value of innovation in decision-making in health care in Central Eastern Europe

T2 - Expert Review of Pharmacoeconomics and Outcomes Research

AU - Novakovic,Tanja

AU - Martin,Antony P.

AU - Parker,Mark

AU - Ferrario,Alessandra

AU - Vukovic,Simo

AU - Łanda,Krzysztof

AU - Duba,Jaroslav

AU - Dankó,Dávid

AU - Kotsopoulos,Nikolaos

AU - Godman,Brian

AU - Ristic,Jelena

AU - Stefanovic,Danka

AU - Tesic,Danka

PY - 2017/12/31

Y1 - 2017/12/31

N2 - The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia organised a one day international conference on the value of innovation in decision-making in health care in Central and Eastern Europe. The focus of the conference was on reimbursement decisions for medicines using health technology assessment and the use of managed entry agreements (MEAs). The objectives of this conference were firstly to discuss the challenges and opportunities with the use of MEAs in Central and Eastern European countries; secondly the role of patient registries especially with outcome based schemes, and finally new approaches to improve accessibility to new medicines including better managing their entry.

AB - The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia organised a one day international conference on the value of innovation in decision-making in health care in Central and Eastern Europe. The focus of the conference was on reimbursement decisions for medicines using health technology assessment and the use of managed entry agreements (MEAs). The objectives of this conference were firstly to discuss the challenges and opportunities with the use of MEAs in Central and Eastern European countries; secondly the role of patient registries especially with outcome based schemes, and finally new approaches to improve accessibility to new medicines including better managing their entry.

KW - managed entry agreements

KW - health technology assessment

KW - innovation

KW - Central and Eastern Europe

UR - http://www.tandfonline.com/loi/ierp

U2 - 10.1080/14737167.2017.1385394

DO - 10.1080/14737167.2017.1385394

M3 - Article

VL - 17

SP - 519

EP - 521

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 6

ER -